Answers are grounded in this paper and cite their sources.
Antibody-induced complement activation may cause injury of the neuromuscular junction (NMJ) and is thus considered as a primary pathogenic factor in human myasthenia gravis (MG) and animal models of experimental autoimmune myasthenia gravis (EAMG). In this study, we tested whether CRIg/FH, a targeted complement inhibitor, could attenuate NMJ injury in rat MG models. We first demonstrated that CRIg/FH could inhibit complement-dependent cytotoxicity on human rhabdomyosarcoma TE671 cells induced by MG patient-derived IgG
No takes yet. Share an insight, caveat, or question.
Robert O. Gjerdingen (1986) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: